Linda M Griffith

Linda M Griffith

UNVERIFIED PROFILE

Are you Linda M Griffith?   Register this Author

Register author
Linda M Griffith

Linda M Griffith

Publications by authors named "Linda M Griffith"

Are you Linda M Griffith?   Register this Author

33Publications

1024Reads

49Profile Views

SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery.

Blood 2018 10 28;132(17):1737-1749. Epub 2018 Aug 28.

Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-03-840702DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6202916PMC
October 2018

Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.

N Engl J Med 2018 01;378(1):35-47

From the Duke University Medical Center (K.M.S., O.C., E.W.S.C.) and RTI International (D.W.), Durham, and Rho Federal Systems Division, Chapel Hill (L.K.-E., A.P., B.E., S.C.) - all in North Carolina; National Institute of Allergy and Infectious Diseases, Bethesda, MD (E.A.G., B.W., L.M.G., J.S.G.); Colorado Blood Cancer Institute, Denver (P.A.M., R.A.N.); University of Texas McGovern Medical School (M.D.M.) and M.D. Anderson Cancer Center (C.H.) - both in Houston; Vanderbilt University, Nashville (L.J.C., K.P.); University of Michigan, Ann Arbor (D.K., J.R.S.); Case Western Reserve University and University Hospitals, Cleveland (R.J.F.); University of Alabama, Birmingham (S.M.); Boston University, Boston (R.W.S.); University of Virginia, Charlottesville (K.B.); University of Washington (M.H.W., D.E.F.) and the Fred Hutchinson Cancer Research Center (G.E.G., S.H.) - both in Seattle; University of California, Los Angeles, Los Angeles (J.G., S.K., D.E.F.); City of Hope National Medical Center, Duarte, CA (S.F.); Medical University of South Carolina, Charleston (R.M.S.); Mayo Clinic, Scottsdale, AZ (L.G.); University of Calgary, Calgary, AB, Canada (J.S., S.L.); Washington University, St. Louis (R.B.); Medical College of Wisconsin, Milwaukee (M.E.C., C.K.-T.); Ottawa Hospital Research Institute, Ottawa (C.B.); University of Pittsburgh, Pittsburgh (T.M., R.T.D.); and University of Toledo Medical Center, Toledo, OH (M.B.K.).

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846574PMC
http://dx.doi.org/10.1056/nejmoa1703327DOI Listing
January 2018

Manufacture of Autologous CD34 Selected Grafts in the NIAID-Sponsored HALT-MS and SCOT Multicenter Clinical Trials for Autoimmune Diseases.

Biol Blood Marrow Transplant 2017 Sep 30;23(9):1463-1472. Epub 2017 Jun 30.

Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2017.05.018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5761325PMC
September 2017

National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report.

Biol Blood Marrow Transplant 2017 Jun 14;23(6):870-881. Epub 2016 Oct 14.

University of Florida Health Cancer Center, Gainesville, Florida; Bone Marrow Transplant Program, Division of Hematology/Oncology, University of Florida College of Medicine, Gainesville, Florida.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2016.10.001DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5392182PMC
June 2017

High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS.

Neurology 2017 Feb 1;88(9):842-852. Epub 2017 Feb 1.

From the Colorado Blood Cancer Institute (R.A.N.), Denver; Baylor College of Medicine (G.J.H.), Houston, TX; Ohio State University (M.K.R., S.M.D.), Columbus; MD Anderson Cancer Research Center (U.P.), Houston, TX; Rho, Inc. (K.C.S.), Chapel Hill, NC; National Institute of Allergy and Infectious Diseases (L.M.G.), National Institutes of Health, Bethesda, MD; Division of Brain Sciences (P.A.M.), Imperial College London, UK; City of Hope National Medical Center (H.O.), Duarte, CA; Immune Tolerance Network (P.H.S.), University of California San Francisco; University of Texas Southwestern (O.S.), Dallas; NeuroRx (D.L.A.), McGill University, Montreal, Canada; Fred Hutchinson Cancer Research Center (G.E.G.), University of Washington (M.H.W., A.W., G.H.K.); and Swedish Hospital Medical Center (J.D.B.), Seattle, WA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000003660DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5331868PMC
February 2017

Primary Immune Deficiency Treatment Consortium (PIDTC) update.

J Allergy Clin Immunol 2016 08 22;138(2):375-85. Epub 2016 Apr 22.

Pediatric Immunology and Pediatrics, Mother and Child Ste-Justine Hospital, University of Montreal, Montreal, Quebec, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaci.2016.01.051DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986691PMC
August 2016

Survey on retransplantation criteria for patients with severe combined immunodeficiency.

J Allergy Clin Immunol 2014 Feb 10;133(2):597-9. Epub 2013 Dec 10.

Division of Immunology and the Manton Center for Orphan Disease Research, Children's Hospital Boston, Boston, Mass; Harvard Stem Cell Institute, Harvard Medical School, Boston, Mass.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaci.2013.10.022DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3960313PMC
February 2014

Treatment of immunodeficiency: long-term outcome and quality of life.

J Allergy Clin Immunol 2008 Dec;122(6):1065-8

Department of Pediatrics and Immunology, Baylor College of Medicine, and the Allergy and Immunology Service, Texas Children's Hospital Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaci.2008.10.033DOI Listing
December 2008

Chronic Graft-versus-Host Disease--implementation of the National Institutes of Health Consensus Criteria for Clinical Trials.

Biol Blood Marrow Transplant 2008 Apr;14(4):379-84

Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbmt.2008.01.005DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2293302PMC
April 2008